eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2020
vol. 7
 
Share:
Send email
Share:
abstract:
Review paper

A summary of novel biologics for asthma treatment

Roxana Drygała
1
,
Klaudia Waszczykowska
1
,
Marta Węgierska
1

1.
Department of Immunopathology, Division of Biomedical Science, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
Alergologia Polska – Polish Journal of Allergology 2020; 7, 2: 98–105
DOI: https://doi.org/10.5114/pja.2020.96130
Online publish date: 2020/06/24
View full text Get citation
 
PlumX metrics:
Over 235 million people struggle with asthma. Many patients suffering from a severe type of asthma have a problem with disease control. In this case, basic treatment like high-dose inhaled corticosteroids may not have a suitable effect. With the present level of knowledge about phenotypes and endotypes of asthma, there is a way to customise a more personalised and effective type of medication for every patient. Omalizumab was the first novel type of therapy, and almost 20 years since its approval, it is still one of the most commonly prescribed biologics for asthma treatment. Now, new types of innovating biologics are being invented. This overview presents drugs that are being investigated for treatment or have already been approved.
keywords:

asthma, biologics, interleukins



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.